Clinical trial
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients
NCT01334892 is registered in ClinicalTrials.gov with Pari Pharma GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients
- Lead sponsor
- Pari Pharma GmbH
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- December 31, 2009
- Completion date
- December 31, 2014
- Enrollment
- 130 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.